BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25591547)

  • 1. Causes of drug shortages in the legal pharmaceutical framework.
    De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Legal features of the drug advertising.
    Pashkov VM; Olefir AA; Bytyak OY
    Wiad Lek; 2017; 70(1):133-138. PubMed ID: 28343208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug shortages: a complex health care crisis.
    Fox ER; Sweet BV; Jensen V
    Mayo Clin Proc; 2014 Mar; 89(3):361-73. PubMed ID: 24582195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New regulatory strategies to manage medicines shortages in Europe.
    Musazzi UM; Di Giorgio D; Minghetti P
    Int J Pharm; 2020 Apr; 579():119171. PubMed ID: 32092455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the European union achieved a single pharmaceutical market?
    Timur A; Picone G; DeSimone J
    Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them.
    Hernandez I; Sullivan SD; Hansen RN; Fendrick AM
    J Manag Care Spec Pharm; 2024 Jul; 30(7):719-727. PubMed ID: 38950157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.